Navigation Links
Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
Date:10/5/2009

ROCHESTER, N.Y., Oct. 5 /PRNewswire/ -- Bausch & Lomb, the global eye health company, today announced it has acquired the commercial assets of Tubilux Pharma S.p.A.

Tubilux is a privately held ophthalmic pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products primarily in Italy, and with distribution in approximately 30 other countries.

Under the terms of the agreement, Bausch & Lomb has acquired the company's ophthalmic pharmaceuticals portfolio, as well as its commercial and sales operations. Group Tubilux will retain its manufacturing operation, producing existing products for Bausch & Lomb under a multi-year contract.

"This agreement more than doubles our presence in the Italian ophthalmic pharmaceuticals market," said Charl van Zyl, head of Bausch & Lomb's Pharmaceuticals business for Europe, Middle East and Africa. "Bausch & Lomb is committed to expanding our portfolio offerings, and we believe that this investment will prove successful for the company, doctors and patients alike."

The acquired Tubilux portfolio includes products for dry eye relief (Oxyal, Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); for anti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).

"As a result of this transaction, Tubilux will strengthen its focus and presence in the ophthalmic pharmaceutical contract manufacturing sector, including ointments, gels and eye drop formats," said Emidio Fedeli, chief executive officer of Group Tubilux.

Sal Oppenheim Jr. & Cie. KGaA Milan Branch acted as the sole financial advisor of Group Tubilux in this transaction.

Financial terms of the agreement will not be made public.

About Bausch & Lomb

Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.

SOURCE Bausch & Lomb


'/>"/>
SOURCE Bausch & Lomb
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
2. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
3. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
4. Robbins & Myers Announces Regular Quarterly Cash Dividend
5. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
6. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
9. U.S. Preventive Medicine Acquires Specialty Disease Management
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... the ralinepag phase 2 trial.  Ralinepag is an oral, ... the treatment of pulmonary arterial hypertension (PAH). The study ... "This marks an important step in the development of ... our pipeline," said Amit Munshi , Arena,s President ...
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink Inc ... for connecting the Life Sciences supply chain and ... today announced that Tjoapack has selected TraceLink,s serialization ... customers comply with the rapidly approaching serialization deadlines ... (DSCSA) in 2017 and the EU Falsified Medicines ...
(Date:12/7/2016)... ZIONA SCIENCE PARK , ... biotechnology company Kadimastem (TASE: KDST) announced today the signing of a ... collaboration between the companies. The synergy between the companies will assist ... collaboration as a worldwide leader in innovative treatment for severe diseases ... ...
Breaking Medicine Technology:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... Scottsdale, AZ (PRWEB) , ... ... ... pioneer, ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus ... , WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg Leyer, the ... Probiotic Association’s Washington DC workshop on November 2nd. The conference was an opportunity ... probiotic dietary supplement regulations. , Dr. Leyer spoke about two main topics ...
(Date:12/6/2016)... ... 2016 , ... The International Vaccine Institute (IVI) and GeneOne ... Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development ... in the event of a future outbreak. , IVI and GeneOne held a ...
Breaking Medicine News(10 mins):